Navigation Links
Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
Date:9/9/2008

cer of the Canadian Medical Discoveries Fund, a biotech venture capital fund. Dr. Stiller has authored more than 265 medical and scientific papers and has received a significant number of awards throughout his career for his medical contributions and entrepreneurship. Additionally, he has co-founded many organizations and programs including the Ontario Institute for Cancer Research.

In welcoming Dr. Stiller to Jennerex' board, Chairman Brennan Mulcahy commented that, "Dr. Stiller brings a wealth of medical and biotech experience to Jennerex, as well as extensive experience with emerging biotech companies. As Jennerex develops its corporate structure to support its clinical trials program, Dr. Stiller's counsel will be invaluable in guiding the board and management through a critical period in the company's development."

"I am excited to join the board of Jennerex at this exciting stage of its development," said Dr. Stiller. "The JX-594 lead product, as well as other offerings in this product class, have great potential to change cancer care and to develop significant market penetration for these novel therapeutics. I am very impressed with the Jennerex team which has made huge progress to date in a relatively short time, and with great efficiency in use of capital," added Dr. Stiller.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeat
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure
8. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
9. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
10. NuVasive Completes Acquisition of Osteocel Biologics Business
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Texas (PRWEB) March 05, 2015 ... of acute and chronic orthopedic conditions such as ... knee, tennis elbow, and joint pain due to ... be administered during orthopedic surgeries to promote better ... scientific advances in nearly pain-free bone marrow harvesting ...
(Date:3/4/2015)... March 4, 2015 The UPMC Center for ... Fellows in the Emerging Leaders in Biosecurity Initiative (ELBI). ... in the field of biosecurity, UPMC has selected 28 ... wide array of backgrounds, including biological science, medicine, policy, ... "With the vision and support of the ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... to biological systems? Until now, says Prof. Ron Naaman ... both biologists and physicists have considered quantum systems and ... research he conducted together with scientists in Germany, which ... a biological molecule DNA can discern between ...
... Tiens Biotech Group (USA), Inc. (the "Company" or "Tiens", NYSE ... to the research, development, manufacturing, and marketing of nutrition supplement ... announced financial results for the year ended December 31, 2010. ... $62.0 million for 2009.   Net income for ...
... SHANGHAI, March 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... leading developer, manufacturer and distributor of probiotics products in ... product sales order from its newly signed U.S. customer. ... its first sales order, and formally entered into its ...
Cached Biology Technology:Biological molecules select their spin 2Tiens Biotech Group (USA) Reports 2010 Results 2Tiens Biotech Group (USA) Reports 2010 Results 3Tiens Biotech Group (USA) Reports 2010 Results 4Tiens Biotech Group (USA) Reports 2010 Results 5Tiens Biotech Group (USA) Reports 2010 Results 6Tiens Biotech Group (USA) Reports 2010 Results 7China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... existence of life in outer space may have a surprisingly ... Understanding how life evolved on Earth is important in obtaining ... find life and what it might be like, said George ... is finishing work on a three-year research grant from NASA's ...
... attracts developing sensory nerves up the spinal cord toward ... in the opposite direction, down the cord and away ... Chicago in the September 2005 issue of Nature Neuroscience ... restore function to people with paralyzing spinal cord injuries. ...
... computer simulation whose results have enhanced scientific understanding ... by the National Institutes of Health, appears in ... the National Academy of Sciences. , Previous research ... histone proteins and DNA--exhibits salt-dependent conformations. Specifically, chains ...
Cached Biology News:Evolution of life on Earth may hold key to finding life in outer space 2Evolution of life on Earth may hold key to finding life in outer space 3Gradient guides nerve growth down spinal cord 2Gradient guides nerve growth down spinal cord 3
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
GBL Antibody...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
... [SPM278] to 67kD Laminin Receptor, prediluted ... live cells (Human). Reactivity / Specificity ... in other species. Background Information ... basement membrane, displays multiple biological activities which ...
Biology Products: